In the pharma industry, an early access program (EAP) is a way to get treatments to patients who have unmet medical needs before the product is widely available.
An EAP may be an option for patients who have exhausted all other treatment options and are not eligible for clinical trials. Patients in an EAP receive the treatment directly from the pharmaceutical company.
EAPs are not available for all new treatments, and not all patients who want an early access treatment will be able to get one. Pharmaceutical companies decide who is eligible for an EAP based on the unmet medical need of the patient and other factors.